methyl (E)-3-(3-aminophenyl)acrylate | 58186-45-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: methyl (E)-3-(3-aminophenyl)acrylate
• 英文别名: (E)-methyl 3-(3-aminophenyl)acrylate；3-(3-amino-phenyl)-acrylic acid methyl ester；methyl (E)-3-(3-aminophenyl)prop-2-enoate
• CAS: 58186-45-1
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: VCSGRXIKJCLEAN-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 储存条件：
  2-8°C，存放在干燥、密封且避光的环境中。

反应信息

• 作为反应物：
  描述：

  methyl (E)-3-(3-aminophenyl)acrylate 在 盐酸 、 盐酸羟胺 、 碳酸氢钠 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 39.17h， 生成 贝利司他
  参考文献：
  名称：

  [EN] SOLID STATE FORMS OF (2E)-N-HYDROXY-3-[3-(PHENYLSULFAMOYL)PHENYL]PROP-2-ENAMIDE AND PROCESS FOR PREPARATION THEREOF
  [FR] FORMES À L'ÉTAT SOLIDE DE (2E)-N-HYDROXY-3-[3- (PHÉNYLSULFAMOYL) PHÉNYL] PROP-2-ÉNAMIDE ET LEUR PROCÉDÉ DE PRÉPARATION

  摘要：

  本发明涉及以下结构式-1所代表的（2E）-N-羟基-3-[3-(N-苯磺酰基)苯基]丙-2-烯酰胺的固态形式以及其制备方法。

  公开号：

  WO2018029699A1
• 作为产物：
  描述：

  3-硝基肉桂酸 在 乙醇 、 硫酸 、 tin(ll) chloride 作用下， 生成 methyl (E)-3-(3-aminophenyl)acrylate
  参考文献：
  名称：

  Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies

  摘要：

  多发性骨髓瘤是一种致命的癌症，是一种复杂的多因素疾病。

  DOI：

  10.1039/d2ra01969h

文献信息

• Synthesis of 2‐( <i>N</i> ‐cyclicamino)quinoline combined with methyl ( <i>E</i> )‐3‐(2/3/4‐aminophenyl)acrylates as potential antiparasitic agents
  作者：Fostino R. B. Bokosi、Richard M. Beteck、Dustin Laming、Heinrich C. Hoppe、Tendamudzimu Tshiwawa、Setshaba D. Khanye

  DOI：10.1002/ardp.202000331

  日期：2021.7

  A rationally designed series of 2-(N-cyclicamino)quinolines coupled with methyl (E)-3-(2/3/4-aminophenyl)acrylates was synthesized and subjected to in vitro screening bioassays for potential antiplasmodial and antitrypanosomal activities against a chloroquine-sensitive (3D7) strain of Plasmodium falciparum and nagana Trypanosoma brucei brucei 427, respectively. Substituent effects on activity were

  合成了一系列合理设计的 2-( N-环氨基)喹啉与甲基 ( E )-3-(2/3/4-氨基苯基)丙烯酸酯，并进行了体外筛选生物测定，以确定对氯喹的潜在抗疟原虫和抗锥虫活性分别是恶性疟原虫和布氏锥虫427 的敏感 (3D7) 菌株。评估了替代物对活性的影响；元-丙烯酸酯24和邻位-丙烯酸酯29表现出最高的抗疟原虫（IC 50  = 1.4μM）和抗锥体虫（IC 50 = 10.4 µM) 活动，分别。对 HeLa 细胞的活性表明合成的类似物在最大测试浓度下没有细胞毒性。通过 SwissADME 软件预测合成化合物的 ADME（吸收、分布、代谢和排泄）类药物特性。
• Selective Reduction of Nitrocinnamoylfumagillols with α,β-Unsaturated Ester Using Borohydride Exchange Resin (BER)-Nickel Acetate
  作者：Hong Woo Lee、Joong Bok Ahn、Jung Hwa Lee、Sung Kwon Kang、Soon Kil Ahn、Sang Joon Lee

  DOI：10.3987/com-05-10425

  日期：——

  Borohydride Exchange Resin (BER) - nickel acetate system readily reduces nitrocinnamoylfumagillols to the corresponding amines in excellent yields, high chemoselectivity, and simple procedure. Especially, this system tolerates two epoxides (spiro-epoxide and the one on C4 alkene side chain) and the α,β-unsaturated ester moiety at C6 on the fumagillol.

  硼氢化物交换树脂 (BER) - 醋酸镍系统可轻松将硝基烟酰烟碱还原为相应的胺，收率高、化学选择性高且程序简单。特别是，该系统耐受两种环氧化物（螺环氧化物和 C4 烯烃侧链上的一种）和烟曲霉醇 C6 上的 α,β-不饱和酯部分。
• TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
  申请人：Curis, Inc.

  公开号：US20130102595A1

  公开（公告）日：2013-04-25

  The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：（1）识别患有与K-ras突变相关的癌症的受试者；和（2）向受试者施用（i）PI3激酶抑制剂和（ii）HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以联合治疗有效的剂量进行施用。
• [EN] TREATMENT OF CANCERS HAVING K-RAS MUTATIONS<br/>[FR] TRAITEMENT DE CANCERS PRÉSENTANT DES MUTATIONS K-RAS
  申请人：CURIS INC

  公开号：WO2011130628A1

  公开（公告）日：2011-10-20

  The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：(1) 鉴定患有与K-ras突变相关的癌症的受试者；和 (2) 给予该受试者 (i) PI3激酶抑制剂和 (ii) HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以治疗有效的剂量一起给予。
• Discovery and optimization of non-steroidal FXR agonists from natural product-like librariesElectronic supplementary information (ESI) available: schemes describing the synthesis of compounds in Fig. 2, 4, 5, 6 and 7. All final compounds were characterized by 1H NMR spectroscopy and HRMS are available on request. See http://www.rsc.org/suppdata/ob/b3/b300525a/
  作者：K. C. Nicolaou、Ronald M. Evans、A. J. Roecker、Robert Hughes、Michael Downes、Jeffery A. Pfefferkorn

  DOI：10.1039/b300525a

  日期：2003.3.13

  The efficient regulation of cholesterol biosynthesis, metabolism, acquisition, and transport is an essential component of lipid homeostasis. The farnesoid X receptor (FXR) is a transcriptional sensor for bile acids, the primary product of cholesterol metabolism. Accordingly, the development of potent, selective, small molecule agonists, partial agonists, and antagonists of FXR would be an important step in further deconvoluting FXR physiology. Herein, we describe the development of four novel classes of potent FXR activators originating from natural product-like libraries. Initial screening of a 10 000-membered, diversity-orientated library of benzopyran containing small molecules for FXR activation utilizing a cell-based reporter assay led to the identification of several lead compounds possessing low micromolar activity (EC50's = 5–10 µM). These compounds were systematically optimized employing parallel solution-phase synthesis and solid-phase synthesis to provide four classes of compounds that potently activate FXR. Two series of compounds, bearing stilbene or biaryl moieties, contain members that are the most potent FXR agonists reported to date in cell-based assays. These compounds may find future utility as chemical tools in studies aimed at further defining the physiological role of FXR and discovering potential therapeutic agents for the treatment of diseases linked to cholesterol and bile acid metabolism and homeostasis.

  胆固醇生物合成的有效调控、代谢、获取和转运是脂质稳态的重要组成部分。法尼醇X受体（FXR）是胆汁酸的转录感应器，胆汁酸是胆固醇代谢的主要产物。因此，开发高效、选择性的小分子FXR激动剂、部分激动剂和拮抗剂将是进一步解析FXR生理功能的重要步骤。本文描述了四种源自天然产物样库的新型高效FXR激活剂的开发。最初利用基于细胞的报告基因检测法对一个含有10,000个成员、以多样性为导向的含苯并吡喃小分子库进行FXR激活筛选，发现了几个具有低微摩尔活性的先导化合物（EC50值为5-10 µM）。通过平行溶液相合成和固相合成系统地优化这些化合物，得到了四种能够高效激活FXR的化合物。其中两个系列的化合物，含有芪或双芳基部分，在基于细胞的检测中，它们是迄今为止报道的最强效的FXR激动剂。这些化合物可能在旨在进一步定义FXR生理作用和发现与胆固醇及胆汁酸代谢和稳态相关疾病潜在治疗药物的研究中作为化学工具发挥未来实用性。